Statistics back up the anecdotal evidence of some stabilization in some patients in the Phase 1. That level of measurable activity with a biomarker for the p53 gene is impressive since they're measuring what happens with only one dose. Given the short half-life of Kevetrin, the 3 dose/week regimen they're planning for the ovarian cancer trial should be even more effective. Very encouraging news for $CTIX, hope people understand what great news this is.